Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOA | P21397 | 3/20 | 0.44 |
| ▸ | MAOB | P27338 | 1/20 | 0.44 |
| ▸ | F10 | P00742 | 10/20 | 0.43 |
| ▸ | F2 | P00734 | 2/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | ITGB3 | P05106 | 4/20 | 0.39 |
| ▸ | ITGA2B | P08514 | 4/20 | 0.39 |
| ▸ | PRSS1 | P07477 | 2/20 | 0.39 |
| ▸ | PRSS2 | P07478 | 2/20 | 0.39 |
| ▸ | PRSS3 | P35030 | 2/20 | 0.39 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.39 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.39 |
| ▸ | HTR6 | P50406 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6614875 | 1.00 | MAOA (0.44) | MAOAMAOBF10F2ALDH1A1 | |
| SCHEMBL3038229 | 0.89 | MAOA (0.53) | MAOAMAOBF10F2ALDH1A1 | |
| SCHEMBL6616635 | 0.83 | MAOB (0.66) | MAOAMAOBF10 | |
| SCHEMBL5763602 | 0.83 | MAOB (0.66) | MAOAMAOBF10 | |
| SCHEMBL6040255 | 0.82 | F10 (0.45) | MAOAMAOBF10F2GRM2 | |
| SCHEMBL5762074 | 0.82 | F10 (0.45) | MAOAMAOBF10F2GRM2 | |
| SCHEMBL5765886 | 0.81 | MAOA (0.63) | MAOAMAOBF10 | |
| SCHEMBL7847879 | 0.80 | MAOA (0.53) | MAOAMAOBF10F2GRM2 | |
| SCHEMBL7847873 | 0.80 | MAOA (0.53) | MAOAMAOBF10F2GRM2 | |
| SCHEMBL4670666 | 0.79 | GRM2 (0.54) | F10GRM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7645781-B2 | N-aryl-2-oxazolidinone-5-carboxamides and their derivatives | PFIZER INC (US) | 2010-01-12 | — | — | US | disclosed |
| US-20070015801-A1 | N-aryl-2-oxazolidinone-5-carboxamides and their derivatives | THOMAS RICHARD C | 2007-01-18 | — | — | US | disclosed |
| US-7141588-B2 | N-aryl-2-oxazolidinone-5-carboxamides and their derivatives | PFIZER, INC. (US) | 2006-11-28 | — | — | US | disclosed |
| EP-1478629-B1 | N-ARYL-2-OXAZOLIDINONE-5-CARBOXAMIDES AND THEIR DERIVATIVES AND THEIR USE AS ANTIBACTERIALS | PHARMACIA & UPJOHN CO LLC (US) | 2006-10-11 | — | — | EP | disclosed |
| US-7049443-B2 | Amide-containing compound having improved solubility and method of improving the solubility of an amide-containing compound | PHARMACIA & UPJOHN COMPANY (US) | 2006-05-23 | — | — | US | disclosed |
| US-6919329-B2 | N-Aryl-2-oxazolidinone-5-carboxamides and their derivatives | PHARMACIA & UPJOHN COMPANY (US) | 2005-07-19 | — | — | US | disclosed |
| EP-1478629-A1 | N-ARYL-2-OXAZOLIDINONE-5-CARBOXAMIDES AND THEIR DERIVATIVES AND THEIR USE AS ANTIBACTERIALS | PHARMACIA & UPJOHN COMPANY (US) | 2004-11-24 | — | — | EP | disclosed |
| EP-1451164-A2 | AMIDE DERIVATIVES HAVING IMPROVED SOLUBILITY | PHARMACIA & UPJOHN COMPANY (US) | 2004-09-01 | — | — | EP | disclosed |
| US-20040147760-A1 | N-aryl-2-oxazolidinone-5-carboxamides and their derivatives | PHARMACIA & UPJOHN COMPANY | 2004-07-29 | — | — | US | disclosed |
| US-20040044052-A1 | N-Aryl-2-oxazolidinone-5-carboxamides and their derivatives | PHARMACIA & UPJOHN COMPANY | 2004-03-04 | — | — | US | disclosed |
| US-20040014967-A1 | Amide-containing compound having improved solubility and method of improving the solubility of an amide-containing compound | PHARMACIA & UPJOHN COMPANY | 2004-01-22 | — | — | US | disclosed |
| WO-2003072553-A1 | N-ARYL-2-OXAZOLIDINONE-5-CARBOXAMIDES AND THEIR DERIVATES AND THEIR USE AS ANTIBACTERIALS | PHARMACIA & UPJOHN COMPANY (US) | 2003-09-04 | — | — | WO | disclosed |
| WO-2003006440-A2 | AMIDE-CONTAINING COMPOUND HAVING IMPROVED SOLUBILITY AND METHOD OF IMPROVING THE SOLUBILITY OF AN AMIDE-CONTAINING COMPOUND | PHARMACIA & UPJOHN COMPANY (US) | 2003-01-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040147760-A1 | N-aryl-2-oxazolidinone-5-carboxamides and their derivatives | OXA1L, AADAC, MT-ND5 | MAOA 957/4885MAOB 976/4885F10 4479/4885 |
| US-20040044052-A1 | N-Aryl-2-oxazolidinone-5-carboxamides and their derivatives | OXA1L, AADAC, MT-ND5 | MAOA 957/4885MAOB 976/4885F10 4479/4885 |
| US-20040014967-A1 | Amide-containing compound having improved solubility and method of improving the solubility of an amide-containing compound | AADAC, AAAS, SLC7A1 | MAOA 1179/4885MAOB 732/4885F10 2380/4885 |
| US-20070015801-A1 | N-aryl-2-oxazolidinone-5-carboxamides and their derivatives | OXA1L, AADAC, MT-ND5 | MAOA 957/4885MAOB 976/4885F10 4479/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.